IBM Introduces Identity and Control for AI Agents, Securing Frontier Intelligence for the Enterprise
Enterprises are deploying agents faster than they can verify them. HashiCorp Vault uses Agent Identity to give each agent a ...
In patients with previously treated advanced/metastatic KRAS G12C NSCLC, divarasib improves survival compared with sotorasib ...
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Nec ...
As a cornerstone of Merck & Co.’s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone. | As a ...
Long-Term OS Results With Lenvatinib Plus Pembrolizumab and TACE in HCC / cancer, cancer care, Cancer research, cancer ...
In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary ...
In Panku-Lung01, iza-bren, an EGFRxHER3 ADC, significantly reduced the risk of progression or death by 60% compared with ...
And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...
As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of ...
Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma ...
In patients with muscle-invasive bladder cancer (MIBC), treatment with neoadjuvant durvalumab and enfortumab vedotin, with or ...
SigVie-002 failed to improve OS with sigvotatug vedotin vs docetaxel, while a post hoc second-line analysis showed a PFS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results